157 related articles for article (PubMed ID: 17287337)
21. Vinflunine: a new vision that may translate into antiangiogenic and antimetastatic activity.
Aparicio LM; Pulido EG; Gallego GA
Anticancer Drugs; 2012 Jan; 23(1):1-11. PubMed ID: 22027536
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of 4-aza-2,3-dihydropyridophenanthrolines as tubulin polymerization inhibitors.
Kamal A; Srinivasa Reddy T; Polepalli S; Paidakula S; Srinivasulu V; Ganga Reddy V; Jain N; Shankaraiah N
Bioorg Med Chem Lett; 2014 Aug; 24(15):3356-60. PubMed ID: 24953821
[TBL] [Abstract][Full Text] [Related]
23. Tricyclic pyrone analogs: a new synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, microtubule assembly, the viability of leukemic cells in vitro and the growth of solid tumors in vivo.
Perchellet EM; Ladesich JB; Magill MJ; Chen Y; Hua DH; Perchellet JP
Anticancer Drugs; 1999 Jun; 10(5):489-504. PubMed ID: 10477169
[TBL] [Abstract][Full Text] [Related]
24. Studies toward diazonamide A: initial synthetic forays directed toward the originally proposed structure.
Nicolaou KC; Snyder SA; Huang X; Simonsen KB; Koumbis AE; Bigot A
J Am Chem Soc; 2004 Aug; 126(32):10162-73. PubMed ID: 15303892
[TBL] [Abstract][Full Text] [Related]
25. New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies.
Wilson L; Jordan MA
J Chemother; 2004 Nov; 16 Suppl 4():83-5. PubMed ID: 15688618
[TBL] [Abstract][Full Text] [Related]
26. Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Reddy JA; Dorton R; Bloomfield A; Nelson M; Vetzel M; Guan J; Leamon CP
Clin Cancer Res; 2014 Apr; 20(8):2104-14. PubMed ID: 24429878
[TBL] [Abstract][Full Text] [Related]
27. Mechanism of inhibition of cell proliferation by Vinca alkaloids.
Jordan MA; Thrower D; Wilson L
Cancer Res; 1991 Apr; 51(8):2212-22. PubMed ID: 2009540
[TBL] [Abstract][Full Text] [Related]
28. Chemistry and biology of diazonamide A: first total synthesis and confirmation of the true structure.
Nicolaou KC; Chen DY; Huang X; Ling T; Bella M; Snyder SA
J Am Chem Soc; 2004 Oct; 126(40):12888-96. PubMed ID: 15469286
[TBL] [Abstract][Full Text] [Related]
29. Microtubule active agents: beyond the taxane frontier.
Morris PG; Fornier MN
Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832
[TBL] [Abstract][Full Text] [Related]
30. [Antitumor effect of compounds synthesized in the Division of Synthetic Chemistry (IV) (author's transl)].
Miyahara M; Kamiya S; Nakadate M; Sueyoshi S; Tanno M; Miyahara M; Maekawa A; Odashima S
Eisei Shikenjo Hokoku; 1980; 98():123-5. PubMed ID: 7248613
[No Abstract] [Full Text] [Related]
31. [Cl958].
Lansiaux A; Caty A; Deligny N; Bailly C
Bull Cancer; 2002 Jun; 89(6):575-8. PubMed ID: 12135857
[No Abstract] [Full Text] [Related]
32. The molecular pharmacology of symplostatin 1: a new antimitotic dolastatin 10 analog.
Mooberry SL; Leal RM; Tinley TL; Luesch H; Moore RE; Corbett TH
Int J Cancer; 2003 Apr; 104(4):512-21. PubMed ID: 12584751
[TBL] [Abstract][Full Text] [Related]
33. [Microtubules and antineoplastic drugs].
Arioka H; Saijo N
Gan To Kagaku Ryoho; 1994 Apr; 21(5):583-90. PubMed ID: 7908790
[TBL] [Abstract][Full Text] [Related]
34. Oxidative rearrangement of indoles: a new approach to the EFHG-tetracyclic core of diazonamide A.
Poriel C; Lachia M; Wilson C; Davies JR; Moody CJ
J Org Chem; 2007 Apr; 72(8):2978-87. PubMed ID: 17367196
[TBL] [Abstract][Full Text] [Related]
35. Tubulin-binding agents down-regulate matrix metalloproteinase-2 and -9 in human hormone-refractory prostate cancer cells – a critical role of Cdk1 in mitotic entry.
Chang WL; Yu CC; Chen CS; Guh JH
Biochem Pharmacol; 2015 Mar; 94(1):12-21. PubMed ID: 25615907
[TBL] [Abstract][Full Text] [Related]
36. The total syntheses of phorboxazoles--new classics in natural product synthesis.
Haustedt LO; Hartung IV; Hoffmann HM
Angew Chem Int Ed Engl; 2003 Jun; 42(24):2711-6. PubMed ID: 12820252
[No Abstract] [Full Text] [Related]
37. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
Brogdon CF; Lee FY; Canetta RM
Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
[TBL] [Abstract][Full Text] [Related]
38. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
[TBL] [Abstract][Full Text] [Related]
39. A novel anti-microtubule agent with carbazole and benzohydrazide structures suppresses tumor cell growth in vivo.
Ohira M; Iwasaki Y; Tanaka C; Kuroki M; Matsuo N; Kitamura T; Yukuhiro M; Morimoto H; Pang N; Liu B; Kiyono T; Amemiya M; Tanaka K; Yoshida K; Sugimoto N; Ohshima T; Fujita M
Biochim Biophys Acta; 2015 Sep; 1850(9):1676-84. PubMed ID: 25960391
[TBL] [Abstract][Full Text] [Related]
40. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
